A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Butler
Javed
J
Giamouzis
Grigorios
G
Giannakoulas
Georgios
G
D000208:Acute Disease; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004280:Dobutamine / Q000008:administration & dosage / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage* / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain / Q000097:blood / Q000187:drug effects; D011724:Pyridazines / Q000008:administration & dosage* / Q000627:therapeutic use; D000077464:Simendan; D015996:Survival Rate; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D020097:Natriuretic Peptide, Brain; D000077464:Simendan; D004280:Dobutamine